Study wrapper · #1084
Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.
Alfonso Arvez MJ, Wade S, Goordeen D, et al. Clinical pharmacology and therapeutics. 2026.
DOI: 10.1002/cpt.70414PubMed: 42533561
Editor's note
This prescription-sequence analysis reports semaglutide as the dominant agent and finds inverse associations with later antidepressant and substance-use medication starts. The design detects temporal patterns but cannot establish causation or rule out confounding by indication. Regard the inverse associations as signals warranting dedicated study rather than evidence of a therapeutic effect.
Plain-language abstract
Using Australian prescription data, this analysis found that starting a GLP-1 receptor agonist (semaglutide being the most common) was associated with lower subsequent initiation of antidepressants and substance-use-disorder medications. No associations were seen for other neuropsychiatric medication categories.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026